MN-25 (UR-12) is a drug invented by

Bristol-Myers Squibb The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...

, that acts as a reasonably selective

agonist An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ag ...

of peripheral cannabinoid receptors. It has moderate affinity for CB₂ receptors with a ''K''_i of 11 nM, but 22x lower affinity for the psychoactive CB₁ receptors with a ''K''_i of 245 nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a ''K''_i of 8 nM at CB₁ and 29 nM at CB₂, which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB₂ (cf. JWH-018 vs JWH-007, JWH-081 vs JWH-098). Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, Org 28611, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in JWH-200 or

A-796,260 A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB2 receptor agonist. Replacing the aromatic 3-benzoyl or 3- naphthoyl group found in most indole derived cannabinoids with the 3- tetramethylcy ...

. Early compounds such as these have subsequently led to the development of many related indole-3-carboxamide cannabinoid ligands.

See also

References

Further reading